Lilly lowers EPS guidance as Zyprexa returns to growth
This article was originally published in Scrip
Executive Summary
Lilly's third-quarter income swung to a profit of $942 million compared with a loss of $466 million in the same period last year on the back of solid performances by its lead products and revenue from the acquisition of ImClone last year.